Overview

Study for Identifying Optimal Simvastatin Formulation for Uniform Time to Maximum Plasma Concentration

Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The inter- and intra-variability in the pharmacokinetic parameters of different formulations and doses of simvastatin in healthy subjects and in subjects with celiac disease in remission will be evaluated. Additionally, baseline values of pharmacokinetic parameters of simvastatin for both study groups will be determined.
Phase:
Phase 1
Details
Lead Sponsor:
University of Zurich
Collaborator:
Stanford University
Treatments:
Simvastatin